Dapagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Dapagliflozin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
1089
Registered trials
492
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Dapagliflozin can convert its Small molecule drug profile and SGLT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Dapagliflozin (query alias: dapagliflozin) |
|---|---|
| Modality / target | Small molecule drug; SGLT2; SGLT2 inhibitors |
| Highest global status | Approved |
| Originator | Bristol Myers Squibb Co. |
| Active developers | AstraZeneca PLC, Bristol Myers Squibb Co., AstraZeneca AB |
The MCP disease footprint includes Diabetes Mellitus, Type 1, Chronic heart failure, Chronic Kidney Diseases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07684326 | Phase 2/3 | Recruiting | 52 | Number of times patient need Paracentesis to control Ascites |
| ChiCTR2600127990 | Not Applicable | Not yet recruiting | 60 | Between-group difference in HbA1c change from baseline at 12 weeks. |
| ChiCTR2600128007 | Not Applicable | Completed | 36 | Pharmacokinetics |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled Trial
Phase 3; n=208; evaluation: Negative. Reported fields: -; BMI = -0.7 kg/m2
2474-P: Comparable Hepatic Benefits with Differential Effects on Triglycerides and Glycemic Control: A 24-Week Prospective Study
Not Applicable; n=54; evaluation: Positive. Reported fields: HbA1c: P-Value = 0.04; HbA1c: P-Value = 0.04
1839-P: Real-World Effectiveness and Safety of Dapagliflozin/Glimepiride/Metformin Fixed-Dose Combinations (FDC) in Indian Adults with Type 2 Diabetes Mellitus (T2DM): Insights from BENEFACTOR Study
Not Applicable; n=3770; evaluation: Positive. Reported fields: AE = 7.9 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Dapagliflozin addresses Diabetes Mellitus, Type 1, Chronic heart failure, Chronic Kidney Diseases. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-03-02 | Ono Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan | Approved | Financial terms not disclosed |
| 2026-01-27 | Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More | Phase 3 | Financial terms not disclosed |
| 2018-02-28 | Daewoong to distribute AstraZeneca's Forxiga and Xigduo for type 2 diabetes in Korea | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Specific quantitative detection method for 2-epimer and alpha-isomer in dapagliflozin”. The milestone feed surfaced a patent-application signal described as “GLP1r agonist and SGLT-2 inhibitor combination therapy”. The milestone feed surfaced a patent-application signal described as “Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
